A phase II trial of brentuximab vedotin (BV) and lenalidomide (Len) in relapsed and refractory (r/r) cutaneous (CTCL) and peripheral (PTCL) T-cell lymphomas. (2019) - Maakaron, J.; Huang, Y.; Brammer, J.; Chung, C.; William, B.